BioCentury
ARTICLE | Company News

Altea, Amylin, Eli Lilly deal

April 6, 2009 7:00 AM UTC

Altea granted Lilly and Amylin exclusive, worldwide rights to develop and commercialize transdermal exenatide using Altea's PassPort Transdermal Delivery System. The once daily transdermal exenatide patch is in Phase I testing for Type II diabetes. Altea will receive an undisclosed upfront payment and is eligible for up to $46 million in milestones, plus royalties. Lilly and Amylin also will each make an undisclosed equity investment in Altea. ...